Twist Bioscience Corp
TWST34.021USD
-1.019-2.91%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.04BCap. mercado
PérdidaP/E TTM
Más Datos de Twist Bioscience Corp Compañía
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Información de la empresa
Símbolo de cotizaciónTWST
Nombre de la empresaTwist Bioscience Corp
Fecha de salida a bolsaOct 31, 2018
Fundada en2013
Director ejecutivoDr. Emily M. Leproust, Ph.D.
Número de empleados923
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 31
Dirección681 Gateway Blvd.
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono18007190671
Sitio Webhttps://www.twistbioscience.com/
Símbolo de cotizaciónTWST
Fecha de salida a bolsaOct 31, 2018
Fundada en2013
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
343.35K
-0.63%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
116.05K
-17.54%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.48K
-0.51%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.51K
-1.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
12.60K
+55.04%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
10.70K
-8.04%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
343.35K
-0.63%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
116.05K
-17.54%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
50.48K
-0.51%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
47.51K
-1.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
NGS tools
48.64M
54.83%
Synthetic genes
26.48M
29.85%
Antibody discovery
5.70M
6.42%
Oligo pools
5.09M
5.74%
DNA and Biopharma libraries
2.79M
3.15%
DNA libraries
2.79M
3.15%
Por regiónUSD
Nombre
Ganancia
Proporción
Americas
53.71M
60.54%
EMEA
28.30M
31.91%
APAC
6.70M
7.55%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
NGS tools
48.64M
54.83%
Synthetic genes
26.48M
29.85%
Antibody discovery
5.70M
6.42%
Oligo pools
5.09M
5.74%
DNA and Biopharma libraries
2.79M
3.15%
DNA libraries
2.79M
3.15%
Estadísticas de accionistas
Actualizado: mar., 20 de may
Actualizado: mar., 20 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
10.42%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.35%
Other
55.96%
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
10.42%
The Vanguard Group, Inc.
9.77%
Artisan Partners Limited Partnership
9.77%
BlackRock Institutional Trust Company, N.A.
7.73%
William Blair Investment Management, LLC
6.35%
Other
55.96%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
51.92%
Investment Advisor/Hedge Fund
49.22%
Hedge Fund
8.42%
Research Firm
3.10%
Individual Investor
1.98%
Pension Fund
1.42%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.27%
Family Office
0.24%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
565
67.44M
112.56%
-7.04M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
2023Q1
593
64.77M
113.93%
-4.20M
2022Q4
610
60.52M
106.86%
-2.15M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARK Investment Management LLC
6.38M
10.7%
+786.30K
+14.05%
Feb 28, 2025
The Vanguard Group, Inc.
5.79M
9.71%
+189.79K
+3.39%
Dec 31, 2024
Artisan Partners Limited Partnership
5.89M
9.88%
-125.19K
-2.08%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
4.62M
7.75%
+119.93K
+2.66%
Dec 31, 2024
William Blair Investment Management, LLC
2.95M
4.95%
-527.57K
-15.17%
Dec 31, 2024
Invesco Advisers, Inc.
3.53M
5.92%
+25.56K
+0.73%
Dec 31, 2024
State Street Global Advisors (US)
2.54M
4.26%
-623.36K
-19.68%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
2.61M
4.38%
-248.70K
-8.69%
Dec 31, 2024
Thrivent Asset Management, LLC
1.51M
2.52%
+532.04K
+54.64%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
ARK Genomic Revolution ETF
6.34%
iShares Genomics Immunology and Healthcare ETF
2.62%
ARK Innovation ETF
2.1%
Global X Genomics & Biotechnology ETF
2.01%
WisdomTree BioRevolution Fund
1.82%
Franklin Genomic Advancements ETF
1.65%
ROBO Global Healthcare Technology & Innovation ETF
1.15%
BNY Mellon Innovators ETF
1.13%
Putnam Sustainable Future ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.85%
Ver más
ARK Genomic Revolution ETF
Proporción6.34%
iShares Genomics Immunology and Healthcare ETF
Proporción2.62%
ARK Innovation ETF
Proporción2.1%
Global X Genomics & Biotechnology ETF
Proporción2.01%
WisdomTree BioRevolution Fund
Proporción1.82%
Franklin Genomic Advancements ETF
Proporción1.65%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.15%
BNY Mellon Innovators ETF
Proporción1.13%
Putnam Sustainable Future ETF
Proporción0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.85%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
